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Abstract
Background Familial triple-negative breast cancers are often
linked to mutations in the BRCA1 tumor suppressor gene. In
sporadic triple-negative breast cancers BRCA1 is frequently
inactivated at the transcriptional level, and it has been reported
that this inactivation may be brought about by promoter meth-
ylation. More recently, it was found that BRCA1 may also be
regulated at the post-transcriptional level by miRNAs. Here, we
explored the expression of putative BRCA1-regulating
miRNAs in sporadic human triple-negative breast cancer cells.
Methods Nine sporadic human breast cancer-derived cell
lines and one benign breast epithelium-derived cell line were
assessed for their hormone receptor, growth factor receptor
and cytokeratin status by immunocytochemistry. The expres-
sion of 5 selected miRNAs predicted to target BRCA1 was
assessed using qRT-PCR in the 10 cell lines. In addition, ex-
pression profiles of 84 known breast cancer-associated
miRNAs were established in these 10 cell lines using PCR
Array and qRT-PCR, respectively. The putative role of pre-
selected candidate miRNAs in breast cancer development was
assessed through exogenous expression of these miRNAs and
their anti-miRNAs (‘antagomirs’) in MDA-MB-231 and
MCF7 breast cancer-derived cells.
Results Based on our expression profiling results, four candi-
date miRNAs (miR-10b, miR-26a, miR-146a and miR-153)
were selected as being potentially involved in triple-negative
breast cancer development. Exogenous expression assays re-
vealed that miR-10b and miR-26a, but not miR-146a, can
down-regulate the expression of BRCA1 in both triple-
negative MDA-MB-231 and luminal epithelial MCF7 breast
cancer-derived cells, whereas miR-153 could down-regulate
BRCA1 expression only in MCF7 cells. In silico analysis of
The Cancer Genome Atlas (TCGA) data confirmed that miR-
146a is significantly higher expressed in triple-negative breast
tumors compared to other (non triple-negative) breast tumors.
Conclusion Our work provides evidence for the involvement
of specific miRNAs in triple-negative breast cancer develop-
ment through regulating BRCA1 expression.
Keywords MicroRNAs .Human triple-negativebreastcancer
cells . BRCA1 . Regulation
1 Introduction
Breast cancer is the most commonly diagnosed cancer in
women (23 % of all cancers), with an estimated diagnosis of
1.38 million new cases each year worldwide [1–4]. At the
molecular level, breast cancers can be classified in four main
subtypes, depending on the expression of hormone and
growth factor receptors. The luminal subtypes A and B ex-
press both the estrogen receptor (ER) and the progesteron
receptor (PR), the HER2-enriched subtype shows amplifica-
tion and over-expression of the human epidermal growth fac-
tor receptor 2 (HER2), and the triple-negative subtype does
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not express any of these receptors. This classification corre-
lates well with the prognosis, ranging from good for luminal A
tumors to poor for the triple-negative tumors [5, 6]. The latter
category, representing ~10 to 15 % of all breast cancers, is
generally considered aggressive [7, 8].
Triple-negative breast cancers are often linked to in-
activation of the BRCA1 tumor suppressor gene. In fa-
milial breast cancer, 85 % of the BRCA1 mutated tu-
mors are triple-negative [9, 10]. In sporadic triple-
negative breast cancers, BRCA1 is frequently inactivated
at the transcriptional level, and it has been shown that
BRCA1 inactivation may be due to methylation of its
promoter brought about by ID4 [11, 12]. More recently
it has been found that BRCA1 may also be regulated at
the post-transcriptional level by microRNAs [13].
MicroRNAs (miRNAs) are small non-coding 19–25
nucleotide-long RNAs that can post-transcriptionally
regulate gene expression by binding to the 3’untranslat-
ed regions (3 ′-UTR) of target messenger RNAs
(mRNAs), thereby leading to mRNA degradation or
translational repression [14–16]. miRNAs have been
shown to be involved in diverse biological processes
[17–19]. In human breast cancer it has been shown that
they can act either as tumor suppressors (i.e., miR-206,
miR-17-5p, miR-125a, miR-125b, miR-200, let-7, miR-
34 and miR-31) or as oncogenes (i.e., miR-21, miR-
155 , miR-10b , miR-373 and miR-520c) [20] .
Previously, it has been shown that BRCA1 gene expres-
sion is relatively low in ER-negative and high-grade
breast cancers [21] and that BRCA1 gene expression is
significantly down-regulated in triple-negative breast
cancers [22]. The number of miRNAs that may regulate
the expression of BRCA1 or that may serve as transcrip-
t ional targets of BRCA1 is rapidly increasing.
Considering the tumor-suppressive role of BRCA1, any
perturbation in this regulatory function is likely to have
an effect on BRCA1-mediated tumor development [23].
Moskwa et al. reported that miR-182-mediated down-
regulation of BRCA1 can impede DNA repair and, as such,
affect breast cancer therapy [24]. It has also been shown that
miR-146a and miR-146b-5p can down-regulate the expres-
sion of the BRCA1 gene in triple-negative sporadic breast
cancers [18]. In contrast, a recent study reported that miR-
146a expression levels increased simultaneously with
BRCA1 expression levels. In addition, it was suggested that
post-transcriptional regulation of epidermal growth factor re-
ceptor (EGFR) expression by BRCA1 may be mediated by
miR-146a [25].
Here, we investigated miRNA expression profiles in nine
human breast cancer-derived cell lines and one benign breast
epithelium-derived cell line. By doing so, we identified a set
of miRNAs putatively involved in BRCA1 gene expression
regulation and breast cancer development.
2 Materials and methods
2.1 Cell culture
Nine selected human breast cancer-derived cell lines and one
benign breast epithelium-derived cell line (Table 1) were cul-
tured in a humified incubator at 37 °C containing 5 % CO2.
Cell line MCF10a was obtained from the American Type
Culture Collection (ATCC; Manassas, VA, USA) and was
cultured in DMEM/F12 medium (Invitrogen Life
Technologies, Carlsbad, CA, USA) supplemented with 10 %
horse serum, 20 ng/ml EGF, 100 ng/ml cholera toxin,
500 ng/ml hydrocortisone, 2 mM L-glutamine and 20 ng/ml
gentamicin.
Cell lines MCF7, T47D, MDA-MB-231, HCC1937 and
MDA-MB-436 were also obtained from the ATCC and were
cultured in RPMI-1640 medium (Invitrogen Life
Technologies, Carlsbad, CA, USA) supplemented with 10 %
fetal bovine serum (FBS), 2 mM L-glutamine and 20 ng/ml
gentamicin. Cell lines SUM149PT and SUM1315MO2 were
obtained from Asterand (Royston, Hertfordshire, UK) and
were grown in Ham’s F12 medium according to the supplier’s
instructions. Cell lines SUM1315-LXSN and SUM1315-
BRCA1 were derived from the BRCA1 mutated (185delAG)
SUM1315MO2 cell line, stably transfected with empty LXSN
or LXSN-BRCA1 plasmids, respectively. The BRCA1 muta-
tion status of the other cell lines has previously been reported
by Elstrodt et al. [26].
2.2 Immunocytochemistry
Cells were fixed in Preservcyt solution (Thinprep) and
cytoblocks were prepared using a Shandon Cytoblock kit
(Thermo Scientific). The estrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor 2
(HER2), cytokeratin5/6, cytokeratin14, epidermal growth fac-
tor receptor (EGFR) and tyrosine kinase receptor cKIT protein
status was determined by immunocytochemistry on 3 μm-
thick sections. Immunostainings were performed in a
BenchmarkXT fully automatized stainer (Ventana Medical
Systems) and scored semi-quantitatively by an expert pathol-
ogist under a light microscope.
2.3 MiRNA target prediction algorithms
Five available algorithms predicting miRNA-mRNA interac-
tions were used to select miRNAs targeting the 3′-UTR of the
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microcosm/htdocs/targets/v5/) and.PicTar (http://pictar.mdc-
berlin.de/cgi-bin/PicTar_vertebrate.cgi).
For all algorithms we used the default parameters and we
selected miRNAs that putatively target BRCA1 by at least
three algorithms.
2.4 RNA extraction, reverse transcription
and quantitative real-time PCR
Total cell RNA was extracted using QIAzol reagent
(Qiagen miRNeasy mini kit) according to the manufac-
turer’s instructions. The RNA quality and yields were
assessed using an Agilent Bioanalyzer 2100 (Kit Agilent
RNA 6000 nano) in conjunction with a spectrophotometer.
One microgram of total RNA was reverse-transcribed using
a miscript II RT kit (Qiagen, France). 15 nanograms of
cDNA was used in triplicate for quantitative real-time
PCR using a miscript SYBER Green PCR kit (Qiagen,
France) on an ABI7900HT system and an Applied
Biosystems ViiA™ 7 Real-Time PCR system. Selected
miRNA primers were obtained from miScript Primer
Assay (Qiagen, France) and are listed in supplementary
Table S1. U6 (Hs-RNU6-2–1 miscript Primer Assay) and
18S rRNA were used as internal controls. All samples were
normalized to the internal controls and fold changes were
calculated through relative quantification (RQ = 2-ΔΔCT).
2.5 PCR array-based profiling
The Human Breast Cancer miScript miRNA PCR Array
(MTHS-109ZE-4) was used according to the manufacturer’s
protocol (Qiagen, France) for the profiling of 84 miRNAs
known or predicted to alter in expression during breast cancer
initiation and/or progression. The protocol enables real-time
PCR profiling of mature miRNA on an ABI7900HTsystem in
combination with a miScript SYBR Green PCR kit, which
contains a miScript Universal Primer (reverse primer), and a
QuantiTect SYBR Green PCR Master Mix. 250 nanogram of
total RNA was reverse-transcribed using a miscript II RT kit
(Qiagen).
2.6 Transfection assays
Selec ted miRNA mimics and miRNA inhibi tors
(‘antagomirs’) were obtained from miScript miRNA Mimic
and miScript miRNA Inhibitor, respectively (Qiagen, France)
and are listed in supplementary Table S2. The siRNA used for
inhibiting BRCA1 gene expression (siBRCA1) was synthe-
sized by Thermo Scientific, Dharmacon (M-003,461–02–
0005, siGENOME SMART pool, Human BRCA1 (672),
5 nmol). Cells were seeded at a density of 300,000 cells per
well in 6-well plates. Twenty-four hours later, miRNAs and
siRNAs were transfected using Lipofectamine 2000 reagent
(Invitrogen, CA, USA) following the manufacturer’s instruc-
tions. As a mock control, cells were transfected with transfec-
tion reagent alone (Tmock). Three days after transfection, the
cells were washed with PBS and recovered for further
analysis.
2.7 Cell proliferation assay
MDA-MB-231 cells andMCF7 cells were collected, seeded at
a density of 3000 cells per well into a 96-well plate and cul-
tured in a humified incubator at 37 °C containing 5 %CO2 for
24 h. Subsequently, the cells were transfected with Tmock
(transfection reagent alone), siBRCA1, miR-146a, anti-miR-
Table 1 Human breast cancer cell lines and their characteristics
Immunocytochemistry
Cell lines BRCA1 status ER PR HER2 ck5/6 CK14 EGFR cKIT
MCF10A Non tumoral Benign wild-type – – – + (90 %) + (80 %) + (100 %) –
MCF7 Tumoral Luminal wild-type 90 % (1+) 40 % (1/2+) – – – – –
T47D Tumoral Luminal wild-type 50 % (1/2+) 80 % (1/2/+) – – – +(40 %) –
MDA-MB-231 Tumoral TN wild-type – – – – – + (100 %) –
HCC1937 Tumoral TN 5382insC – – – + (25 %) + (20 %) + (100 %) –
MDA-MB-436 Tumoral TN 5396+1G>A – – – – – + (90 %) –
SUM149PT Tumoral TN 2288delT – – – + (25%) + (<1%) + (100%) –
SUM1315MO2 Tumoral TN 185delAG – – – – – + (90 %) –
SUM1315-LXSN Tumoral TN 185delAG – – – – – + (60 %) –
SUM1315-BRCA1 Tumoral TN 185delAG+WT – – – – – + (80 %) –
TN: Triple-Negative. The BRCA1mutational status as also the Estrogen Receptor (ER), Progesterone Receptor (PR), HER2 protein, Cytokeratin5/6
(ck5/6), Cytokeratin14 (ck14), Epidermal Growth Factor Receptor (EGFR) and cKIT protein expression status are indicated
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146, miR-153, miR-10b and miR-26a using Lipofectamine
2000 reagent (Invitrogen, CA, USA) according to the manu-
facturer’s protocol. After 48 h in vitro cell proliferation was
evaluated using CCK-8 (Cell Counting Kit-8, Sigma-Aldrich)
according to the manufacturer’s instructions. The absorbance
was determined at 450 nm using a microplate reader. All ex-
periments were performed in triplicate.
2.8 In silico analysis of miRNAs using TCGA
Both clinical and miRNA sequencing data of invasive
breast cancers were downloaded from The Cancer
Genome Atlas (TCGA) database. A total of 519 patients
with information on ER, PR and HER2 status were select-
ed to compare the expression profiles of four selected
miRNAs (miR-10b, miR-26a, miR-146a and miR-153) in
the respective tumors. 88 cases were found to have a neg-
ative ER, PR and HER2 (i.e., triple-negative) phenotype,
whereas 431 cases were positive for at least one of these
receptors.
2.9 Statistical analysis
Student’s t-test was used to assess statistical differences in
mean expression between groups. A p-value ≤ 0.05 was con-
sidered statistically significant.
3 Results
3.1 miR-10b and miR-26a are preferentially expressed
in triple-negative breast cancer-derived cell lines
In order to identify miRNAs implicated in triple-negative
breast cancer, we used a miScript miRNA PCR Array to pro-
file the expression of 84miRNAs considered to be involved in
breast tumorigenesis. Ten cell lines were analyzed: one benign
breast epithelium-derived cell line (MCF10a), two luminal
breast cancer-derived cell lines (MCF7, T47D) and seven
triple-negative breast cancer-derived cell lines (MDA-MB-
2 3 1 , MDA -MB - 4 3 6 , HCC1 9 3 7 , SUM14 9PT,
SUM1315MO2, SUM1315-BRCA1 and SUM1315-LXSN).
The cell lines were characterized by immunocytochemistry as
presented in Table 1. In order to reveal whether particular
miRNAs are specifically involved in triple-negative breast
cancers, we compared their expression in the respective cell
line subgroups. For this analysis we focused on six miRNAs
that were found to be differently expressed in at least two
subgroups by PCR Array, i.e., miR-10b, miR-15b, miR-26a,
miR-155, miR-206 and miR-485-5p (Table 2, Table S3). To
validate the PCR Array results, we performed qRT-PCR anal-
ysis of the six selected miRNAs in the 10 cell lines. Only two
of these miRNAs (i.e., miR-10b and miR-26a) were found to
be well-expressed in these cell lines. The other miRNAs were
expressed at low levels or were not detectable at all. miR-10b
was highly expressed in 3 triple-negative breast cancer cell
lines (MDA-MB-231, MDA-MB-436 and SUM1315MO2)
(Fig. 1a). miR-26a was found to be expressed in all 10 cell
lines, and to be higher expressed in the triple-negative cell
lines than the luminal cell lines (MCF7, T47D) (Fig. 1b).
3.2 miR-146a and miR-153 target the 3′-UTR of BRCA1
BRCA1 gene expression is frequently down-regulated in
triple-negative breast cancers. We hypothesized that the iden-
tification of miRNAs targeting the 3′-UTR of BRCA1 might
be used to uncover miRNAs involved in the development of
triple-negative breast cancers. To this end, we performed an in
silico computational search using five available algorithms:
TargescanHuman [27], Tarbase [28], Miranda [29],
MicroCosmTargets [30] and PicTar [31].
For all algorithms we used default parameters, and we se-
lected miRNAs predicted to target BRCA1 by at least three
algorithms. From the selected miRNAs (listed in Table S4),
we chose five miRNAs, i.e., two miRNAs (miR-146a and
miR-146b-5p) that were previously found to be over-
expressed in breast tumors and to down-regulate BRCA1 ex-
pression [18] and three miRNAs (miR-132, miR-212, miR-
153) that were most frequently predicted to interact with the
3′-UTR of BRCA1. We validated the expression of these five
selected miRNAs by qRT-PCR in the 10 cell lines and found
that miR-146a was higher expressed in 3 triple-negative breast
cancer cell lines: MDA-MB-231, MDA-MB-436 and
SUM1315-BRCA1 (Fig. 1c), that miR-153 was higher
expressed in 4 triple-negative breast cancer cell lines: MDA-
MB-436, SUM1315MO2, SUM149PT and HCC1937
(Fig. 1d), and that miR-146b-5p, miR-132 and miR-212 were
expressed in all 10 cell lines at different levels (Fig. S1) with-
out a significant difference between the triple-negative, lumi-
nal or benign cell lines. Based on these results we focused our
further analyses, next to miR-10b and miR-26a, on miR-146a
and miR-153.
3.3 BRCA1 expression is regulated by miR-10b, miR-26a
and miR-153
The above expression profiling and in silico analyses allowed
us to select 4 miRNAs, miR-10b, miR-26a, miR-146a and
miR-153 for further analysis. To determine the effect of these
miRNAs on endogenous BRCA1 expression, we transfected
two BRCA1 wild-type cell lines (MDA-MB-231 and MCF7)
with the respective miRNAs (miRNA mimics) and anti-
miRNAs (inhibitors or ‘antagomirs’). The efficiency of the
miRNA mimics and inhibitors was verified by miRNA quan-
tification using qRT-PCR (Fig. S2), revealing sufficient effi-
ciencies only for miR-10b, miR-26a, miR-146a, anti-miR-
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146a and miR-153. The BRCA1 siRNA efficiency was also
tested and found to be sufficient (Fig. S3). Since MCF7 is a
luminal cell line andMDA-MB-231 a triple-negative cell line,
our data can potentially reveal whether the miRNAs tested
may have a different effect on BRCA1 in these two subtypes
of breast cancer.
To determine whether miR-146a affects endogenous
BRCA1 expression, we compared the expression level in
MDA-MB-231 and MCF7 cells after transfection with miR-
146a, anti-miR-146a and a mock control (transfection reagent
alone). By doing so, we found that miR-146a does not appear
to regulate the expression of BRCA1 (Fig. 2). Next, we tested
the effect of miR-153 on the expression ofBRCA1. The results
obtained (Fig. 2) indicate that miR-153 can down-regulate the
expression of BRCA1 in MCF7 cells. In contrast, we found
that in MDA-MB-231 cells miR-153 induced BRCA1 up-reg-
ulation. After miR-10b transfection into MDA-MB-231 and
MCF7, the BRCA1expression level was found to be decreased
in both of them (Fig. 2). These results suggest that miR-10b
can down-regulate the expression of BRCA1 in MDA-MB-
231 and MCF7 cells. After miR-26a transfection into MDA-
MB-231 and MCF7 cells, the expression level of BRCA1 was
again found to be decreased in both of them (Fig. 2), indicat-
ing that also miR-26a can down-regulate the expression of
BRCA1 in MDA-MB-231 and MCF7 cells.
3.4 EGFR expression is not regulated by miR-146a
in MDA-MB-231 and MCF7 cells
Kumaraswamy et al. reported that BRCA1 can induce miR-
146a expression which, in turn, can repress EGFR expression
in mammary cells [25]. To determine whether miR-146a can
affect endogenous EGFR expression in our cell lines,
we compared its expression level in MDA-MB-231
and MCF7 cells after transfection with miR-146a, anti-
miR-146a, Tmock (transfection reagent alone) and
siBRCA1 (Fig. S4). After doing so, we found that in
these cell lines miR-146a had no effect on the expres-
sion of EGFR.
3.5 Stimulation and inhibition of cell proliferation
by miRNAs
To assess the effect of miR-10b, miR-26a, miR146a, anti-
miR-146a and miR-153 on MDA-MB-231 and MCF7 cell
proliferation, the cells were transfected with the respective
(anti-) miRNAs, as also siBRCA1 and Tmock (transfection
reagent alone). In MDA-MB-231 cells, the proliferation assay
(see materials and methods) showed that miR-26a sig-
nificantly stimulated and that miR-146a inhibited prolif-
eration compared to mock-transfected cells. In MCF7
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cells, miR-153, miR-10b and miR-26a significantly
inhibited proliferation compared to mock-transfected
cells (Fig. 3).
3.6 Differential expression of miR-10b, miR-26a,
miR-146a and miR-153 in TCGA
TCGAwas queried for the expression of miR-10b, miR-26a,
miR-146a and miR-153 in different primary breast cancer
tissues. As shown in Fig. 4 the average expression of miR-
153 andmiR-10bwas found to be significantly lower in triple-
negative tumors (p = 0.00045 and p = 0.00038, respectively)
than in luminal tumors, while the expression of miR-146a was
found to be significantly higher in triple-negative tumors
(p = 0.000005). For miR-26a, the difference in average ex-
pression was not found to be significant in these tumors
(p = 0.6234).
4 Discussion
Triple-negative breast cancers, representing ~10 to 15 % of all
human breast cancers, have gained growing interest in recent
years [32]. In addition, the role of microRNAs (miRNAs) in
the epigenetic regulation of many cellular processes has in-
creasingly become recognized as an important way to fine-
tune gene expression [33]. Here, expression profiling,
Fig. 1 Expression of miRNAs in mammary cell lines. (a) miR-10b ex-
pression level, (b) miR-26a expression level, (c) miR-146a expression
level and (d) miR-153 expression level. miRNA expression was deter-
mined by qRT-PCR in one benign mammary epithelium cell line
(MCF10a) and nine tumor cell lines (two luminal cell lines: MCF7 and
T47D and seven triple-negative cell l ines: MDA-MB-231,
SUM1315MO2, SUM1315-LXSN, SUM1315-BRCA1, MDA-MB-
436, SUM149PT and HCC1937). Expression of miRNAwas normalized
using U6. A p-value < 0.05 is considered significant (between triple-
negative and luminal cell lines)
Fig. 2 BRCA1 expression after miRNA mimic and miRNA inhibitor
transfection in MDA-MB-231 and MCF7 cells. Expression of BRCA1
was determined by qRT-PCR in MDA-MB-231 and MCF7 cells
transfected with Tmock (transfection reagent only), miR-146a, anti-
miR-146a, miR-153, miR10-b and miR-26a. BRCA1 expression was nor-
malized using 18S
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transfection and in silico assays were performed to identify
potential triple-negative breast cancer miRNA biomarkers,
i.e., miR-10b, miR-26a, miR-146a and miR-153.
We found that miR-10b was higher expressed in triple-
negative breast cancer-derived cell lines compared to luminal
breast cancer-derived cell lines. TCGAdata, however, indicated
that the average expression of miR-10b was significantly lower
in triple-negative tumors than in non triple-negative tumors.
O’Day and Lal reported that miR-10b was over-expressed only
in metastatic cancer cells, and was found to promote tumor cell
migration, invasion and metastasis in vivo [20]. Whereas miR-
10b has been found to be highly expressed in several human
cancers [34], Biagioni et al. found that miRNA-10b was down-
regulated in tumor tissues compared to their normal matched
counterparts due to hypermethylation of CpG islands upstream
from the miR-10b/10b* locus [35]. We found that miR-10b can
down-regulate the expression of BRCA1 in MDA-MB-231 and
MCF7 cells. High miR-10b expression may thus be a way to
silence BRCA1 expression in BRCA1 wild-type cells. Recently,
it was reported that miR-10b may also play a critical role in
TGF-induced epithelial-mesenchymal transition (EMT) in
breast cancer and, as such, may be considered as a possible
therapeutic target [36]. Moreover, miR-10b was shown to be
able to promote the invasion and metastasis of tumor cells
through post-transcriptional regulation of HOXD10 [37].
Overall, these results indicate that miR-10b may act as an on-
cogenic miRNA in breast cancer cells. Nevertheless, Biagioni
et al. reported that exogenousmiR-10b expression reduced both
Fig. 3 Proliferation assay after siBRCA1, miRNA mimic and inhibitor
transfection in MDA-MB-231 and MCF7 cells. Cells were transfected
with Tmock (transfection reagent only), siBRCA1, miR-146a, anti-miR-
146, miR-153, miR-10b and miR-26a. After 48 h, in vitro cell prolifera-
tion was evaluated using CCK-8. The absorbance was determined at
450 nm. All experiments were performed in triplicate
Fig. 4 In silico expression
analysis of miRNAs using TCGA
data. Clinical and miRNA
expression data for breast cancer
were downloaded from The
Cancer Genome Atlas (TCGA)
database. The expression of four
miRNAs (miR-10b, miR-26a,
miR-146a and miR-153) was
compared in 88 breast tumors
with a negative ER, PR and
HER2 status (i.e., triple negative
phenotype) and in 431 breast tu-
mors that were positive for at least
one of the receptors. Student’s
t-test was used to assess statistical
differences in mean expression
levels between these two groups
miR-10b, miR-26a, miR-146a, miR-153 as potentiel TNBC biomarkers 439
the in vitro and in vivo proliferative capacities of MCF7 and
MDA-MB-468 cells [35]. Our results are compatible with those
of Biagioni et al., as we found that miR-10b significantly
inhibited the proliferation of MCF7 cells (p = 0.006). Thus,
restoration of miR-10b expression may hold a therapeutic
promise for breast cancer treatment.
Another potential biomarker of triple-negative breast cancer
that we identified is miR-26a, and we found that miR-26a can
down-regulate the expression of BRCA1 in MDA-MB-231 and
MCF7 cells. These results suggest an oncogenic function of this
miRNA in breast cancer. In contrast, Gao et al. reported thatmiR-
26a could inhibit the proliferation and migration of breast cancer
cells through repression of MCL-1, and that miR-26a could in-
crease the sensitivity of breast cancer cells to paclitaxel [38].
Others found that miR-26a can promote ovarian cancer cell pro-
liferation by targeting ERα [39]. We found that miR-26a signif-
icantly stimulated the proliferation of MDA-MB-231 cells and
inhibited the proliferation of MCF7 cells. We also found that the
average expression of miR-26a was not significantly different
between triple-negative and non triple-negative breast tumors in
the TCGA database. The role of miR-26a thus appears to be
complex and may dependent on the tissue and/or tumor context.
Our cell line and TCGA data analyses show that miR-146a
is significantly over-expressed in triple-negative breast can-
cers. Similar results were reported by others [18, 25]. We also
found that miR-146a does not affect the expression of BRCA1
in MDA-MB-231 and MCF7 cells. In contrast, Gracia et al.
reported that miR-146a can down-regulate the expression of
BRCA1 in triple-negative sporadic breast cancers [18]. This
discrepancy may be due to the different cell lines used for the
exogenous expression assays, i.e., Gracia et al. used HeLa
cells and three mammary cell lines (MDA-MB-468, MDA-
MB-157 and MDA-MB-436). Another study reported that
miR-146a can inhibit the invasion and migration of the highly
metastatic human breast cancer cell line MDA-MB-231 [40].
These data are in line with our results showing that miR-146a
can inhibit the proliferation ofMDA-MB-231 cells. In a recent
study it was hypothesized that BRCA1may down-regulate the
expression of the EGFR gene by increasing the miR-146a
level in breast cancer-derived cells (HCC1937) [25]. Our re-
sults are compatible with this hypothesis, as we found an
increase in miR-146a expression in BRCA1 wild-type
SUM1315-BRCA1 cells compared to BRCA1 mutated
SUM1315-LXSN cells.We also found that exogenous expres-
sion of miR-146a decreased the proliferation of MDA-MB-
231 cells that highly express EGFR, but not in MCF7 cells
that do not express EGFR. qRT-PCR assessment of EGFR
expression in exogenous miR-146a expressing MDA-MB-
231 and MCF7 cells revealed that the EGFR gene was not
significantly regulated by this miRNA. Taken together, these
results suggest a complex feedback regulation between miR-
146a and BRCA1, which again most likely depends on the
cellular context.
Using bioinformatic tools, we identified a binding site for
miR-153 in the 3′-UTR of BRCA1. Subsequently, we found
that miR-153 can induce BRCA1 down-regulation in MCF7
cells and up-regulation in MDA-MB-231 cells. These contra-
dictory results reflect those reported in the literature. On one
hand, Anaya-Ruiz et al. reported that silencing of miR-153
significantly inhibited the growth, reduced the proliferation
and induced apoptosis in the triple-negative sporadic breast
cancer-derived cell line MDA-MB-231. These results indicate
that miR-153 may function as an oncogenic miRNA, whose
deregulation could be involved in the initiation and/or devel-
opment of human breast cancer [41]. In another report, Wu
et al. suggested that miR-153 may play an important role in
promoting the proliferation of human prostate cancer cells
and, as such, may represent a novel mechanism of miRNA-
mediated PTEN silencing in prostate cancer cells [42]. These
data are compatible with our finding that BRCA1 up-
regulation by miR-153 had no effect on the proliferation of
MDA-MB-231 cells. On the other hand, Zhao et al. found that
transient transfection of miR-153 into glioblastoma
multiforme stem cells (GBM-SCs) can inhibit their stemness
properties, repress their growth potential and induce apoptosis
[43]. These latter data are consistent with our results in MCF7
cells: although BRCA1 was down-regulated by miR-153, it
inhibit proliferation. This difference in response observed be-
tween MDA-MB-231 and MCF7 cells may be explained by
differences in the endogenous levels of miR-153, i.e., higher
in luminal MCF7 cells and lower in triple-negative MDA-
MB-231 cells. TCGA data analysis also indicated that the
average expression of miR-153 is significantly lower in
triple-negative breast cancers. We conclude that also the func-
tion of miR-153 is complex, and identifying targets of miR-
153 would be an interesting means to better understand its role
in cell proliferation and carcinogenesis-related processes.
In conclusion, we identified miR-10b, miR-26a, miR-146a
and miR-153 as potential triple-negative breast cancer bio-
markers. These miRNAs may be instrumental for the future
design of novel targeted treatment options of these breast can-
cers. This ‘from bench-top to bed-side’ translation remains,
however, challenging [44] and additional research is required
to better understand the function(s) of these miRNAs.
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